• In late April 2026, Pfizer resolved US patent disputes over its cardiomyopathy drug VYNDAMAX by settling with three generic manufacturers, effectively extending its market exclusivity until June 1, 2031 and consolidating the brand’s position after discontinuing VYNDAQEL in the United States.
• This legal outcome gives Pfizer clearer medium-term visibility on a key revenue stream in transthyretin-mediated amyloidosis, at the same time as its oncology portfolio advances with positive Phase 3 data for ELREXFIO in relapsed or refractory multiple myeloma.
• Next, we’ll examine how preserving VYNDAMAX exclusivity to 2031 could influence Pfizer’s investment narrative around patent cliffs and pipeline execution.

Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Pfizer Investment Narrative Recap

To own Pfizer today, you need to believe it can replace declining COVID and loss of exclusivity revenue with its pipeline and recent acquisitions, while keeping its sizeable dividend intact. The VYNDAMAX settlement modestly eases near term patent cliff concerns by extending a key rare disease franchise to 2031, but the biggest overhang remains how effectively Pfizer can backfill upcoming expiries such as Eliquis and Ibrance before they pressure earnings and cash flow.

Among the latest updates, the Phase 3 MagnetisMM-5 win for ELREXFIO in relapsed or refractory multiple myeloma stands out. It reinforces Pfizer’s push to make oncology a second growth pillar beside cardiometabolic and rare diseases, which now include a longer VYNDAMAX tail. Together, these data and the PADCEV priority review in bladder cancer help frame oncology as a central catalyst for how the market may reassess Pfizer’s ability to manage its patent cliffs.

Yet while VYNDAMAX now looks safer through 2031, investors should be aware that...

Pfizer's narrative projects $59.6 billion revenue and $12.8 billion earnings by 2028.

Uncover how Pfizer's forecasts yield a $29.08 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming Pfizer could reach about US$59.8 billion of revenue and US$11.7 billion of earnings by 2029, and the VYNDAMAX and ELREXFIO news could either support that oncology led view or highlight how exposed those forecasts are if patent and pricing risks bite harder than expected.

Explore 22 other fair value estimates on Pfizer - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Pfizer research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Pfizer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pfizer's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.